Yangtze River Pharmaceutical Group led Binhui Biopharm's $47m series B-plus round while Sigfox has been snapped up by UnaBiz for under $30m after raising over $300m.

Funding China-based oncolytic virus therapeutics developer Binhui Biopharm has raised approximately $47m in a series B-plus round led by pharmaceutical group Yangtze River, DealStreetAsia reported yesterday. The round included medical product distributor Jointown Pharmaceutical Group, DNV Capital, Ming Capital and Hubei Provincial High-Tech Industry Investment Group. Intigriti, the Belgium-based operator of an online bug bounty…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.